Exogenous surfactant administration is currently being evaluated for the Acute Respiratory Distress Syndrome (ARDS). Although surfactant supplementation is now a routine therapy for babies born with neonatal RDS, this treatment modality for adults does not appear to result in a predictable improvement in lung function as is noted in neonates. This article will review the basic abnormalities of the surfactant system in patients with ARDS and contrast them with the primary surfactant deficient state of nRDS. Various factors that have been shown to influence an individual's response to exogenous surfactant will the be outlined. Finally, potential treatment approaches for patients with ARDS utilizing exogenous surfactant will be proposed.